NFE2L2 and cancer: Thus, mTORC1 is an important target of cancer treatment. In this study, the mTORC1 signaling pathway was significantly activated in the NFE2L2 mutated patients with NSCLC, implying that TORC1 inhibitors were likely to exhibit considerable therapeutic efficacy in NFE2L2 mutated NSCLC patients.